Immutep faces class action after trial halt causes 82.6% stock drop

Immutep Ltd. announced the discontinuation of its TACTI-004 Phase III trial for lung cancer after an interim analysis showed futility, causing its stock to plunge 82.6%. The Rosen Law Firm is investigating potential securities claims, alleging Immutep misled investors with business information. Investors who bought Immutep securities may join a class action to seek compensation without upfront costs. The law firm highlights its experience in securities litigation and encourages affected shareholders to contact them for participation details.